Sotorasib,a Kirsten rat sarcoma viral oncogene homologue (KRAS)-G12C inhibitor,has demonstrated efficacy in nonsmall cell lung cancer (NSCLC) byselectively targeting mutant KRAS., Microtubule-stabilizingagents like docetaxel and Paclitaxel, are standard chemotherapeuticsfor lung cancer treatment, exerting their effects by disrupting mitoticspindle formation and inducing apoptosis. However, environmental pollutants may interfere with the bindingand efficacy of these drugs, potentially altering their therapeuticpotential. Here, KRAS is linked to non-small cell lung carcinoma.